Mitch is a San Francisco-based hacker and inventor, best known for co-founding 3ware (with J. Peter Herz and Jim MacDonald), his pioneering work in Virtual Reality at VPL Research and inventing TV-B-Gone. He is also President and CTO of Cornfield Electronics.
Author and genomics activist Misha Angrist, PhD, is participant number four in Harvard Medical School’s Personal Genome Project, a groundbreaking research effort created by Dr. George Church, one of the founding forces behind the Human Genome Project and inventor of numerous sequencing technologies. Dr. Angrist’s new book, Here is a Human Being, chronicles his experience as one of the first people on the planet to have his entire genome sequenced. Misha delves deep into the personalities, hopes, and fears surrounding this emerging technology. He brings the reader an intensely personal perspective shaped by his experiences as a researcher and stint as a genetic counselor, but most of all, by his time exploring what his genome means for himself, and the people who share his DNA, his two daughters.
Sonia Arrison is a futurist and policy analyst who has studied
the impact of new technologies on society for more than a decade. A Senior Fellow at the California-based Pacific Research Institute(PRI) and a columnist for TechNewsWorld, she is author of two previous books as well as numerous PRI studies on technology issues. A frequent media contributor and guest, her work has appeared in many publications including CBS MarketWatch, CNN, Los Angeles Times, New York Times, Wall Street Journal, and USA Today. She was also the host of a radio show called “digital dialogue” on the Voice America network and has been a repeat guest on National Public Radio, Tech TV, and CNN’s Headline News.
Often asked for advice on technology issues, Sonia has given testimony and served as an expert witness for various government committees such as the Congressional Advisory Commission on Electronic Commerce and the California Commission on Internet Political Practices. She is an instructor for California’s Command College and serves on the Board of Trustees for Singularity University.
Linda Avey is co-founder and CEO of Curious, Inc., a personal data tracking and analytics platform. Previously, she co-founded 23andMe, the leading personal genetics company. Her early career focused on sales and business development roles in the biopharmaceutical industry in San Francisco, Boston, San Diego, and Washington, D.C. While at Affymetrix and Perlegen Sciences, she focused on development of translational research collaborations with academic and pharmaceutical partners. Linda also worked at Spotfire helping researchers maximize value from scientific data through visualization tools, and at Applied Biosystems during the early days of the human genome project. She graduated from Augustana College with a BA in biology.
Dr. Black has practiced patent law at some of the largest law firms in the U.S. He has handled patent prosecution matters for universities and companies
ranging in size from small startups to Fortune 100 firms.
Before practicing law, Dr. Black was an Assistant Professor at the University of Pittsburgh School of Medicine where he developed vaccines for infectious diseases and cancer. Dr. Black received his postdoctoral training at the Magee Women’s Research Institute in Pittsburgh in the areas of mucosal immunology, molecular biology, and microbiology. Dr. Black has published original research in the Journal of Immunology and Infection & Immunity among other journals. He is a contributor to the recently released book, Gene Profiles in Drug Design, and holds patents for an RNA-based drug technology.
Dr. Black is an Adjunct Professor of Law at the University of Pittsburgh School of Law where he teaches Biotechnology Law
Johanna Blakley, PhD, is the managing director and director of research at the Norman Lear Center, a research and public policy institute that explores the convergence of entertainment, commerce and society. Based at the University of Southern California’s Annenberg School for Communication & Journalism, Blakley performs research on a wide variety of topics, including global entertainment, cultural diplomacy, celebrity culture, digital media and intellectual property law. She has two talks on TED.com: Social Media & the End of Gender and Lessons from Fashion’s Free Culture, which have logged over 500,000 views.
Blakley has overseen two major research initiatives about the impact of intellectual property rights on innovation and creativity – Ready to Share: Fashion & the Ownership of Creativity and Artists, Technology & the Ownership of Creative Content.
Jason Bobe serves as the Executive Director of PersonalGenomes.org and Director of Community for the Personal Genome Project based out of George Church’s lab at Harvard Medical School. The Personal Genome Project seeks to encourage the thoughtful development of personal genomics technology and practices by building frameworks for prototyping and evaluation at increasing scales.
Jason is co-founder of DIYbio.org, an organization that aims to help make biology a worthwhile pursuit for citizen scientists and amateur biologists. DIYbio is fast becoming the organizational hub for amateur biologists worldwide, uniting the movement’s participants through its website, online forums, blog and local chapters.
As Founder of the Children’s Rare Disease Network and the Global Genes Project, Nicole has embarked on the journey to help families affected by rare disease based on her personal experience with a family friend, their struggles and challenges over the course of 2 1⁄2 years while working to find a diagnosis for their son. Realizing these families need an outside champion for all rare disease, she believes that ‘power in numbers’ apply to this effort, and works to create collaborations within the entire rare disease community and build greater public awareness for rare disease, which affects over 30 million within the US. In business, Nicole has held numerous consulting, sales and marketing executive roles in her 20 years in business. Nicole has a passion for launching new products, building new organizations and ‘making the impossible possible’. Nicole has worked with world-class organizations within Life Sciences Media as a founding member and Associate Publisher of The Journal of Life Sciences, has also worked in the Life Sciences Venture Capital Community in media, and in the Pharmaceutical and High Tech Sectors. Organizations include Zoomedia, Burrill & Company, Schering Plough, Imagine Media & CMP Media. A Graduate of the University of California San Diego, with a BA in Political Science and formerly enrolled in the masters program at Pepperdine University. Nicole currently resides in Southern California with her husband and two children, enjoying her role as business woman, mother, wife, coach and outdoor enthusiast.
Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen over $20 million in business transactions. Prior to CDD, Dr. Bunin was an Entrepreneur in Residence with Eli Lilly & Co. Before that he was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, Dr. Bunin led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored “Chemoinformatics: Theory, Practice, and Products” (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and “The Combinatorial Index” (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin is on a patent for Carfilzomib – a selective proteasome inhibitor now in phase 3 clinical trials for multiple myeloma.
Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.
Jill is a reference & instruction librarian at the Brooklyn College Library. She is the subject specialist for computer science, mathematics, physics, psychology, and physical education & exercise science, as well as the administrator for RefWorks.
Her current research interests include open access publishing, art in academic libraries, and peer mentoring among junior library faculty. She has also written and presented on research resources for quantum computing and the relationship between Google and reference librarianship.
Dr. Rhiju Das strives to predict how sequence codes for structure in proteins, nucleic acids, and heteropolymers whose folds have yet to be explored. The Das group uses new computational and experimental tools to tackle the de novo modeling of protein and RNA folds, the high-throughput structure mapping of riboswitches and random RNAs, and the design of self-knotting and self-crystallizing nucleic acids.
Dr. Radoje (Rade) Drmanac, chief scientific officer and co-founder of Complete Genomics since 2006, is a research scientist and inventor in the field of human genome sequencing including techniques such as DNA sequencing-by-hybridization (SBH), genomic microarrays and combinatorial probe ligation. In 1994, he co-founded Hyseq (later Nuvelo) where, as chief scientific officer, he led the effort to discover and patent thousands of genes which formed the basis of Nuvelo’s drug development pipeline. Prior to Hyseq, Rade was a group leader at Argonne National Labs from 1991 to 1994 as part of the Department of Energy’s Human Genome Project. He completed his postdoctoral studies in 1990 in Hans Lehrach’s group at the Imperial Cancer Research Fund in London. He earned his Ph.D. in molecular biology for the conception and pioneering development of SBH technology from Belgrade University, where he also received B.S. and M.S. degrees in molecular biology.
Dr. Dudley is a co-founder and Director of an innovative biopharmaceutical company leveraging informatics and big-data to enable a molecular systems based approach to discover biomarkers and match novel therapies to human disease indications. Prior to that, he was a Bioinformatics Scientist in the Division of Systems Medicine at Stanford University School of Medicine, where he drove novel research in translational bioinformatics approaches to genomic medicine. He has published more than 25 peer-reviewed research articles on topics such as pharmacogenomics, personal genomics, and biomarker discovery featured in journals such as Lancet, Nature Biotechnology, and Nature Molecular Systems Biology. Joel’s most recent work involves large-scale integration of public molecular data to enable systems approaches to drug repositioning and biomarker discovery.
David Ewing Duncan
David Ewing Duncan is an award-winning, best-selling author of seven books published in 19 languages; he is a journalist and a television, radio and film producer and correspondent. His most recent book is the bestseller Experimental Man: What one man’s body reveals about his future, your health, and our toxic world. He is the Chief Correspondent of public radio’s Biotech Nation; and a columnist for Fortune. He is the Director of the Center of Life Science Policy at UC Berkeley. He has been a commentator on NPR’s Morning Edition, and a contributing editor for Wired, Discover and Conde Nast Portfolio. David writes for The New York Times, National Geographic, Harper’s, Atlantic Monthly, the San Francisco Chronicle, and many other publications. He is a former special correspondent and producer for ABC Nightline and a correspondent for NOVA’s ScienceNOW! He has won numerous awards including the Magazine Story of the Year from the American Association for the Advancement of Science. His articles have twice been cited in nominations for National Magazine Awards, and his work has appeared twice in The Best American Science and Nature Writing. He is a graduate of Vassar College and now lives in San Francisco.
Anton Geraschenko is currently a postdoc in the Caltech mathematics department. While he was a graduate student at UC Berkeley, he founded http://mathoverflow.net a Q&A forum for professional mathematicians. MathOverflow has become an extension of how mathematicians work. It provides a way for them to follow activity in their fields, to overcome technical hurdles in their work, and to start fruitful collaborations.
William currently serves as the Head of Academic Outreach for Mendeley, a research management tool for collaboration and discovery.
Most recently, he did assay development for Genalyte, a molecular diagnostics startup. His work involved developing protein, DNA, and small molecule assays on their novel high-throughput assay platform.
William received his PhD from the Tulane University, where he studied under Dr. Darwin Prockop at the Tulane Center for Gene Therapy. His dissertation is entitled “Investigating the Role of Human Multipotent Mesenchymal Stromal Cells in the Repair of Bone”, in which he developed a model of multiple myeloma in mice and used it to test small molecule inhibitors of the interaction between multiple myeloma and bone precursor cells, promoting bone regeneration and repair of osteolytic lesions.
Specialties:His work at Tulane involved self-guided experimental research on the relationship between Human Adult Stem Cells and cancer. His areas of expertise are bone biology, multiple myeloma, adult stem cells, and development of disease models.
Alex is the managing director of 1DegreeBio. Alex worked for four years as an international project manager for the Structural Genomics Consortium, where she helped launch and manage dozens of international initiatives and projects. Alexandra has an Honors Bachelor’s Degree from the University of Toronto in International Relations, a Master of Business Administration (MBA) from Hult International Business School (formerly the Arthur D. Little School of Management), and an Organizational Change Management Certificate from Harvard University. Alexandra has spent the past three years heavily involved in the start-up community, both in Boston and Toronto, and has consulted for small-to-medium sized companies in the area of innovation and strategic growth.
Her current position is Research Assistant Professor in the Department of Hematology & Oncology at the University of Miami Miller School of Medicine.
I conducted my doctoral training in Cancer Biology at the Institute of Cancer Research, London, U.K. under the supervision of Professor Alan Ashworth, before completing a post-doctoral fellowship at the University of Miami under the mentorship of Professor Marc Lippman.
My research focuses on identifying and characterizing genes that regulate breast cancer development and progression using innovative techniques. I hope that doing so will facilitate the translation of this knowledge into useful therapeutic strategies, reducing breast cancer morbidity and mortality. She is a founder of Science Exchange, a marketplace for scheduling scientific experiments at core facilities.
Stephan Kinsella is Senior Fellow of the Ludwig vonMises Institute, Editor of Libertarian Papers, Director of the Center for the Study of Innovative Freedom (C4SIF), and General Counsel for Applied Optoelectronics, Inc. A registered patent attorney, former partner with Duane Morris LLP, and former adjunct professor at South Texas College of Law, he has published numerous articles and books, including Against Intellectual Property (Mises Institute, 2008). He received an LL.M. in international business law from King’s College London, a JD from the Paul M. Hebert Law Center at LSU, and BSEE and MSEE degrees from LSU.
The Riedel-Kruse lab is developing biotic games suited for educational purposes in schools and in public settings like museums. The educational aspects and evaluations are done in collaboration with the group of Prof.Daniel Schwartz (Stanford).
We are also developing biotic online games to crowd-source the scientific method, allowing interested non-scientists to make valuable contributions to bio-medically relevant problems while having fun. We hope that this will also lead to a new form of ‘citizen science’.
Ilya Kupersmidt, Co-Founder, NextBio
Mr. Kupershmidt leads NextBio’s product, scientific computing and content groups. His team includes PhDs and MDs from leading academic institutions with extensive experience in genomics, computational biology and clinical research. Mr. Kupershmidt has a decade of experience in the design and implementation of genomic solutions for organizations involved in basic and translational research, as well as drug discovery. Prior to NextBio, Mr. Kupershmidt was the Director of Professional Services at Silicon Genetics. There he helped develop and customize software solutions for the analysis and management of high throughput data generated by genomic and proteomic technologies. Mr. Kupershmidt joined Silicon Genetics as an early stage startup and successfully worked with hundreds of academic institutions and commercial enterprises. Previously, Mr. Kupershmidt carried out research as a geneticist at the UCSD Howard Hughes Medical Institute where he studied transcriptional mechanisms of gene expression regulation during pituitary development. Mr. Kupershmidt is currently a PhD candidate at the SciLifeLab Institute, in Stockholm, Sweden.
Mr. Love is the Director of Knowledge Ecology International (KEI). Mr. Love is also the U.S. co-chair of the Trans-Atlantic Consumer Dialogue (TACD) Intellectual Property Policy Committee, chair of Essential Inventions, an advisor to the X-Prize Foundation on a prize for TB diagnostics, and a member of the UNITAID Expert Group on Patent Pools, the MSF Working Group on Intellectual Property, the Stop-TB Partnership working group on new drug development, and the Internet Governance Forum (IGF) Dynamic Coalition on Open Standards. He advises UN agencies, national governments, international and regional intergovernmental organizations and public health NGOs, and is the author of a number of articles and monographs on innovation and intellectual property rights. In 2006, Knowledge Ecology International received a MacArthur Award for Creative and Effective Institutions.
Knowledge Ecology International was created in 2006 as a separate entity to carry out work earlier done through the Center for Study of Responsive Law and Essential Information. Mr. Love was employed by the Center for Study of Responsive Law from 1990 to 2006. Mr. Love was previously Senior Economist for the Frank Russell Company, a lecturer at Rutgers University, and a researcher on international finance at Princeton University. He holds a Masters of Public Administration from Harvard University’s Kennedy School of Government and a Masters in Public Affairs from Princeton’s Woodrow Wilson School of Public and International Affairs.
Raymond (www.raymondmccauley.net) is Chief Science Officer at Genomera, working on health collaboration and personal genomics. He has 20 years of experience in the biotech and high tech arenas, with Exponential Biosciences (www.exponentialbio.com), Illumina (http://www.illumina.com/), Ingenuity Systems, QIAGEN Genomics, Applied Carbon, various startups and governmental agencies, and a stint as executive producer for PBS television series at TANSTAAFL Media.
Raymond is on the faculty of Singularity University (singularityu.org), an advisor to two biotech stealth startups, and an active participant in the BioCurious Community Lab (www.biocurious.org), DIYgenomics (www.diygenomics.com), and Quantified Self communities. His background is in computer science, electrical engineering, biochemistry, biophysics, and bioinformatics, including graduate studies at Texas A&M University and Stanford University, with support from the NSF Student Scholar Program and a Lechner Fellowship.
His personal interests include genomic medicine, DIYbio, the citizen science movement, practical nanotechnology, and raising his twin boys to be superheroes.
Rob Meagley is an inventor, scientist with interests in processes and materials for nano-, bio- and MEMS technology. He founded ONE Nanotechnologies, LLC, in August of 2007 to develop and market proprietary technology for the detection and identification individual biomarkers in complex mixtures and to provide consulting services to the nanotechnology, MEMS and biotechnology communities. In 2008 investigations into nanostructured films led to the development of new deposition technology, which is reflected strongly in ONE’s IP Portfolio.
Rob holds a BS from the University of Maryland, College Park (89) and Ph.D. from the University of Delaware (’96) in pharmaceutical synthesis and was a post doctoral fellow at Cornell University (96) the University of California, Berkeley (97). He joined Intel Corporation in 1998, starting with a brief stint in the CMP materials Group, then in the Lithography Materials Group in 1998 (with another brief stint in the Commodity Chemicals Group in 2002), and became the Litho Materials Group’s manager in early 2003. In August of 2004 he was named Intel’s Researcher-in-Residence at Lawrence Berkeley National Laboratory and served there as Intel’s Principle Investigator and Engineering Manager. The team, Molecules for Advanced Patterning (MAP), was focused on the discovery, development and commercialization of advanced lithography materials.
Daniel Mietchen is an evolutionary biophysicist with an interest in the evolution of animal communication systems. An active proponent of open science and an independent consultant in open access and data publishing, he currently serves as the first Wikimedian in Residence on Open Science hosted by the Open Knowledge Foundation, Germany.
Mr. Munos is the founder and chief apostle of InnoThink, a partnership dedicated to bringing evidence-based innovation models to the pharmaceutical industry and its stakeholders. Before that, he was advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of the industry R&D model. His research, which has been published in Nature and Science, has helped stimulate a broad rethinking of the pharmaceutical business model by companies, investors, policymakers, regulators, and patient advocates.
He has presented his findings at numerous meetings sponsored by the National Academies, the Institute of Medicine, the President’s Cancer Panel, the NIH Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, Genome Canada, the American Chemical Society, and the Council for American Medical Innovation as well as leading universities and think-tanks in the U.S. and Europe.
He received his MBA from Stanford University and holds other graduate degrees in economics and animal science from the University of California at Davis and the Institut National Agronomique in Paris, France.
Alex Peake is the founder and CEO of Primer Labs, a startup that creates endless learning games to make all knowledge playable. Alex founded the alternative fashion company Tactical Corsets in 2009. Alex was the editor ofAgile Journal, a web & mobile applications developer atSling, and lead animation editor at Atomic Cartoons.
From a young age, Alex believed that games were going to change the world and he set out to gather the pieces to make it happen. His 3rd grade Open Alternative School allowed students to learn at their own pace, so he and his peers made a competitive game out of completing grade levels as fast as they could. In 4th grade, he designed his first RPG called Realms and taught himself C and HyperCard to computerize it. In middle school he divided his time between all-laptop Computer Immersion and mentoring with Professor Dave Fracchia in the Graphics Lab at Simon Fraser University. He created an online empire simulation game called Mage Princes using play-by-email turn files to bypass FirstClass BBS systems’ lack of game support. Hundreds of players signed up to pay for the sequel which he planned to include more sophisticated military, economic and tradecraft RPG elements to allow players to cooperatively build nations.
Dr. Joyce Peng has established herself as a prominent voice for the application of state-of-the art technologies in the life sciences field. Joyce has been promoting bioinformatics and related products at various organizations and is now marketing director at BGI Americas Corporation. She helped define the product line for Oracle in life sciences as a senior product manager. Subsequently, Joyce established proteomics product directions for Rosetta Biosoftware (a subsidiary of Merck) and managed bioinformatics product sales for North America at Invitrogen. In her position as the Strategic Alliance and Growth Manager at Illumina, Joyce managed the partnership with BGI and advanced the application of various sequencing technologies. Now, in her role as marketing director at BGI Americas, Joyce is active in promoting collaborations and alliances with pharmaceutical and biotechnology organizations for the application of BGI’s world-renowned sequencing services. Joyce holds a Ph.D. in Biology from Caltech.
Carlo Rago, OpenOnward
Adam Regelmann, Quartzy
Adam has conducted academic research since early high school in fields such as chemistry, microbiology, and molecular immunology. He is also a physician, holding both an MD and a PhD. Adam currently functions as the scientific voice of Quartzy. He is passionate about Quartzy’s mission, and personally invites you to contact him regarding your thoughts about Quartzy, the trajectory of science in general, or about how the Quartzy Team can improve the site
Dr Murray-Rust leads a research group in the Department of Chemistry at Cambridge University. Co-creator of the Chemical Markup Language (CML), he has long been a pioneer of data exchange and information-mining in the chemical sciences. Firmly committed to promoting openness and data availability throughout the discipline, he recently started the world-wide molecular matrix, the largest open online repository of molecular information in the world.
Dr. Tomasz Sablinski is the Head of Clinical Development and a member of the Executive Committee of Celtic Therapeutics Development (CTD). Dr. Sablinski joined CTD with twenty eight years of experience in healthcare, including his last fifteen years in the global pharmaceutical industry. His career includes ten years of clinical practice as a surgeon specializing in renal transplantation and general surgery, and several years of basic research in immunobiology.
Prior to joining CTD, Dr. Sablinski served as Vice President at Novartis Pharmaceuticals Corp. in charge of US Clinical Development and Medical Affairs. Prior to this, Dr. Sablinski held several leadership positions at Novartis headquarters including Vice President of Clinical Research and Development and Head of Global-Japanese Coordination. He also held multiple leadership positions in Novartis’ Transplantation Business Unit. He participated in, and supervised numerous NDA and IND submissions in the US, Europe and Japan. Dr. Sablinski earned his MD and his Ph.D. in transplant immunology at Warsaw Medical School and his bachelor degrees at Copernicus College in Warsaw, Poland.
Dr. Shaywitz is a graudate of Harvard College (summa cum laude), and received his MD from the Health Sciences and Technology program at Harvard Medical School and MIT, and his PhD from the Department of Biology at MIT. He trained in internal medicine and endocrinology at MGH, and conducted his post-doctoral research in the Melton lab at Harvard. He gained experience in early clinical drug development in the Department of Experimental Medicine at Merck, then joined the Boston Consulting Group’s Healthcare and Corporate Development practices, where he focused on strategy and organizational design. He is currently Director of Strategic and Commercial Planning at Theravance, a publicly-held drug development company in South San Francisco.
Dr. Shaywitz is a co-founder (with Dennis Ausiello) of the Harvard PASTEUR program, a translational research initiative at Harvard Medical School (www.pasteur.harvard.edu). He is also a founding advisor of Sage, a non-profit medical research initiative (founded by Eric Schadt and Stephen Friend) emphasizing networks and open innovation (www.sagebase.org).
For the last fifteen years, Dr. Shaywitz has contributed commentaries about medicine, science, innovation, and business to a number of popular publications, including The New York Times, The Washington Post, The Wall Street Journal, and The Financial Times. He currently is a regular contributor to Forbes.com.
Dr. Shaywitz is an Adjunct Scholar at the American Enterprise Institute.
Nick Shockey began working with SPARC in early 2007 as an undergraduate and student senator at Trinity University where he passed a resolution supporting the Federal Research Public Access Act through Trinity’s student government. He continued his efforts to support Open Access both nationally, aiding SPARC in its launch of the Right to Research student campaign, and locally, pushing for Open Access on Trinity’s campus. Nick was named a SPARC Innovator for his work on student outreach and advocacy.
After graduating, Nick interned as SPARC’s student outreach fellow in the summer of 2009 where he facilitated the launch of The Student Statement on the Right to Research and organized the first Open Access Student Summit, bringing in student leaders from across the country to outline a strategy for increasing student awareness and engagement in Open Access.
In August 2009, Nick was hired full time as SPARC’s first director of student advocacy where he is responsible for growing SPARC’s relationship with the student community as well as managing the Right to Research Coalition, a group of local, national, and international student organizations that advocate for researchers, universities, and governments to adopt more open scholarly publishing practices. Under Nick’s direction, the coalition has grown to represent over 5.5 million students internationally and has facilitated student lobbying in over two hundred Congressional offices.
Victoria Stodden is an Assistant Professor of Statistics at Columbia University, and completed both her Ph.D. in statistics in 2006 and her MLS in 2007 at Stanford University. Her current research focuses on how pervasive and large-scale computation is changing our practice of the scientific method: especially regarding reproducibility of computational results and the role of legal framing for scientific advancement. She has been a postdoctoral fellow at both Harvard and Yale Law Schools and MIT’s Sloan School of Business, won the Kaltura Writing Competition in 2008, and co-chaired a working group on the National Science Foundation’s Office of Cyberinfrastructure’s Task Force on Grand Challenge Communities (released Dec 2010). She is also a Science Commons fellow, and a nominated member of the Sigma Xi scientific research society. Her webpage is www.stodden.net and she occasionally blogs at blog.stodden.net.
Andreas is an expert on the analysis of ultra high-throughput DNA sequence data and has published methods in whole-genome mammalian assembly, metagenomics, and population genetics. Andreas received his Bachelor’s and Master’s degrees in Electrical Engineering and Computer Science from MIT, and his Ph.D. in Computer Science from Stanford University.
Marty Tenenbaum is the Chairman of CollabRx, a provider of Web-basedapplications and services that help cancer patients and their physicians selectoptimal treatments and trials. Dr. Tenenbaum is also the founder of CancerCommons, an open science community that compiles and continually refines information about cancer subtypes and treatments, based on the literature andactual patient outcomes.
Dr. Tenenbaum was educated at MIT and Stanford in the 1960s. He spent the1970s doing artificial intelligence research at SRI, the 1980s managing computerscience research for Schlumberger, and the 1990s pioneering Internet commerce.He is a fellow and former board member of the American Association for ArtificialIntelligence, and a former consulting professor of Computer Science at Stanford.He currently serves as a director of Patients Like Me, the Public Library of Science,Efficient Finance, and Earth Analytics Group.
David Thomson is a technologist who has worked in a variety of financial services industries including hedge funds, broker dealers, private equity, real estate, and venture capital firms. He recently served as the technical lead for one of the largest Salesforce implementations in the world at UCSF and is now the Technical Alliances Lead for Mulesoft, an open source integration company that provides a “Integration Platform as a Service”. David’s research interests center on how new technologies and platform architectures can enable new incentive structures and transaction models, serving as “social technologies” that can facilitate advancement in scientific progress.
Mat Todd obtained his PhD in organic chemistry from Cambridge
University in 1999, was a Wellcome Trust postdoc at Berkeley, a
college lecturer back at Cambridge, a lecturer at Queen Mary,
University of London and since 2005 has been at the School of
Chemistry, The University of Sydney where he is currently Senior
His research interests include the development of new synthetic
methods, asymmetric catalysis and the interaction of coordination
compounds with biomolecules. He has a growing interest in Open
Science, and how it may be used to accelerate research, with
particularly emphasis on open source drug discovery. He recently
published the results of an experimental open science project that
discovered an improved synthesis of a drug for a neglected tropical
disease, Bilharzia. He is now leading a team working on open source
drug discovery for malaria, which is funded by the Medicines for
Malaria Venture. The aim is to demonstrate the power of completely
open, patentless pharmaceutical research. He is Chair of The Synaptic
Leap, a nonprofit dedicated to open biomedical research and is on the
Editorial Boards of PLoS One, Chemistry Central Journal and
Bilharzia paper link:
Malaria project link:
Andrew W. Torrance joined the KU Law faculty in 2005 and, in 2009, was named a Docking Faculty Scholar, a university-wide program established with a gift from the late Mrs. Meredith Docking to honor faculty members who have distinguished themselves in their early careers. He was also a 2009-10 Fellow in Law, Innovation and Growth at the Searle Center at Northwestern University Law School. In August of 2010, Torrance was invited by Google Inc., to give a Google TechTalk at Google’s main Mountain View campus in California; Google posted his entire presentation, “The Patent Game: Experiments in the Cathedral of Law,” on its YouTube Google TechTalk channel. He received his Ph.D. in biology from Harvard University in 1997 and is a 2000 graduate of Harvard Law School. He earned his Bachelor of Science from Queen’s University in Canada. In 2003, he was named the Hrdy Visiting Professor of Conservation Biology at Harvard University and taught Biodiversity: Science, Policy, and Law at Harvard University from 1999 until his arrival at KU.
He practiced biotechnology patent law at Fish and Richardson PC, the world’s largest intellectual property law firm, after working as a summer associate at both Morrison & Foerster LLC and Fish & Richardson P.C. Next, he served as inhouse patent counsel at Inverness Medical Innovations, a global biotechnology company with headquarters in Boston, and helped start Stirling Medical Innovations, a cardiac diagnostics biotechnology company based in Scotland. He has presented his research across the United States, as well as in Canada, Finland, Scotland, England, France and Germany. His articles have been published in journals such as the Berkeley Technology Law Journal, the Columbia Science and Technology Law Review, the Georgetown International Environmental Law Review, and the Washington University Journal of Law and Policy. Several of his articles have been listed on SSRN (Social Science Research Network) Top Ten Lists. In the spring of 2009, Torrance was invited to present his research to the OECD (Organisation for Economic Cooperation and Development) at OECD Headquarters in Paris.
Since 2007, Torrance has run Biolaw: Law at the Frontiers of Biology, an annual conference that gathers leading scholars at KU Law to present their insights on the latest developments in biolaw. His interests in biology have led to research expeditions to Australia, New Zealand, Fiji, Hawaii, Banks Island in the Canadian High Arctic, and the Caribbean islands of Saint Thomas, Saint John, Jost van Dyke and Tortola. He has served as chairman of the Scientific and Creative Board of the Darwin Project, a major biodiversity institution planned for downtown Boston, is a member of the board of East Wind Power, and has assisted the BioBricks Foundation (BBF).
Torrance’s research interests include intellectual property, patent law, innovation law, biotechnology, biolaw, food and drug law, biodiversity law, climate change law, and international environmental law. He teaches classes in intellectual property law, patent law, food and drug law, and biodiversity law. He served as marshall at the law school’s December 2008 hooding ceremony after being elected for the role by the graduating class.
Torrance was featured with Princeton geneticist Lee Silver in a Kansas Public Radio story about the emergence of biolaw as an academic field, was quoted in the Salina Journal on the subject of intellectual property protection of genetically modified crops, and was commissioned by the magazine BioIT World to analyze the ACLU’s lawsuit to overturn Myriad Genetics’ patents covering genetic tests for diagnosing susceptibility to breast and ovarian cancer. An article in the Chronicle of Higher Educationreferenced the Patent Game project that Torrance is collaborating on with William Tomlinson at the University of California-Irvine. Recently, he has been quoted extensively in the Kansas City Star (“Patent lawyers give your big idea an edge”), the Chicago Lawyer (“Bringing predictability to the patent world”), the San Francisco Chronicle (“Patents’ growing role in battle of mobile”), and Dow Jones Newswires (“Biogen sues MS drug makers, citing Avonex patent”). The National Public Radio station KCUR broadcast an interview with Torrance (“Legal roadblocks to copyrighting natural remedies”) on its program “KC Currents.” Torrance was quoted in an ABC 49 News story about the Westboro Baptist Church being under fire for potential copyright infringement for its parody of the song “We Are the World.”